1
|
Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J Immunother Cancer 2024; 12:e008378. [PMID: 38641350 PMCID: PMC11029323 DOI: 10.1136/jitc-2023-008378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/22/2024] [Indexed: 04/21/2024] Open
Abstract
BACKGROUND Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite their potential, these therapies have had limited success in late-phase trials for advanced cancer resulting in few formal approvals. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to determine how to design clinical trials with the greatest chance of demonstrating the benefits of intratumoral immunotherapy for patients with cancers across all stages of pathogenesis. METHODS An Intratumoral Immunotherapy Clinical Trials Expert Panel composed of international key stakeholders from academia and industry was assembled. A multiple choice/free response survey was distributed to the panel, and the results of this survey were discussed during a half-day consensus meeting. Key discussion points are summarized in the following manuscript. RESULTS The panel determined unique clinical trial designs tailored to different stages of cancer development-from premalignant to unresectable/metastatic-that can maximize the chance of capturing the effect of intratumoral immunotherapies. Design elements discussed included study type, patient stratification and exclusion criteria, indications of randomization, study arm determination, endpoints, biological sample collection, and response assessment with biomarkers and imaging. Populations to prioritize for the study of intratumoral immunotherapy, including stage, type of cancer and line of treatment, were also discussed along with common barriers to the development of these local treatments. CONCLUSIONS The SITC Intratumoral Immunotherapy Clinical Trials Expert Panel has identified key considerations for the design and implementation of studies that have the greatest potential to capture the effect of intratumorally delivered immunotherapies. With more effective and standardized trial designs, the potential of intratumoral immunotherapy can be realized and lead to regulatory approvals that will extend the benefit of these local treatments to the patients who need them the most.
Collapse
Affiliation(s)
- Jason J Luke
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
| | - Diwakar Davar
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
| | | | - Nina Bhardwaj
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Joshua D Brody
- Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Jason Chesney
- James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA
| | | | - Thierry de Baere
- Center for Biotherapies In Situ (BIOTHERIS), INSERM CIC1428, Interventional Radiology Unit, Department of Medical Imaging, Gustave Roussy Cancer Center, University of Paris Saclay, Villejuif, France
| | - Tanja D de Gruijl
- Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
- Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands
- Cancer Immunology, Amsterdam Institute for Infection and Immunology, Amsterdam, Netherlands
| | - Matthew Fury
- Oncology Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA
| | | | - Kevin J Harrington
- The Institute of Cancer Research, The Royal Marsden National Institute for Health and Care Research Biomedical Research Centre, London, UK
| | - Howard Kaufman
- Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
- Ankyra Therapeutics, Boston, Massachusetts, USA
| | - Ciara M Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | | | - Ke Liu
- Marengo Therapeutics, Inc, Cambridge, Massachusetts, USA
| | - Sherene Loi
- Division of Cancer Research, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
- The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
| | - Georgina V Long
- Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, North Sydney, New South Wales, Australia
| | | | - Mark Middleton
- Department of Oncology, University of Oxford, Oxford, UK
| | - Bart Neyns
- Department of Medical Oncology, Universitair Ziekenhuis Brussel, Jette, Belgium
| | - David J Pinato
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK
- Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - Rahul A Sheth
- Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Stephen B Solomon
- Chief of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
- Professor of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - Philippe Szapary
- Interventional Oncology, Johnson & Johnson, New Brunswick, New Jersey, USA
| | - Aurelien Marabelle
- Center for Biotherapies In Situ (BIOTHERIS), INSERM CIC1428, Department for Therapeutic Innovation and Early Phase Trials (DITEP), Gustave Roussy Cancer Center, University of Paris Saclay, Villejuif, France
| |
Collapse
|
2
|
Schuetze SM, Ballman KV, Heise R, Ganjoo KN, Davis EJ, George S, Burgess MA, Choy E, Shepard DR, Tinoco G, Hirbe A, Kelly CM, Attia S, Deshpande HA, Schwartz GK, Siontis BL, Riedel RF, von Mehren M, Kozlowski E, Chen HX, Astbury C, Rubin BP. A Single Arm Phase 2 Trial of Trametinib in Patients With Locally Advanced or Metastatic Epithelioid Hemangioendothelioma. Clin Cancer Res 2024:735082. [PMID: 38446990 DOI: 10.1158/1078-0432.ccr-23-3817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 02/06/2024] [Accepted: 03/04/2024] [Indexed: 03/08/2024]
Abstract
PURPOSE Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer with pathogenic TAZ-CAMTA1 operating as an oncogenic driver through activation of MAPK pathway. Trametinib is an inhibitor of MEK, a critical kinase in the MAPK pathway. We sought to evaluate the effect of trametinib in patients with EHE. PATIENTS AND METHODS A phase 2 trial of trametinib was conducted in patients with locally advanced or metastatic EHE. Eligibility requirements included evidence of tumor progression or presence of EHE-related pain requiring opiates for management prior to enrollment. The primary endpoint was objective response rate (ORR) per RECIST1.1 in cases with TAZ-CAMTA1 confirmed by fusion-FISH. Secondary objectives were to estimate ORR for all patients, median PFS, 2-year OS rate, patient safety, and change in patient-reported global health and pain scores per PROMIS questionnaires. RESULTS 44 patients enrolled and 42 started trametinib. TAZ-CAMTA1 was detected in 27 tumor samples. The ORR was 3.7% (95% CI: 0.094, 19.0), median PFS was 10.4 months (95% CI: 7.1, NA), and 2-year OS rate was 33.3% (95% CI: 19.1, 58.2) in the target population. Median pain intensity and interference scores improved significantly after 4 weeks of trametinib in patients using opiates. Common AEs related to trametinib were rash, fatigue, nausea/vomiting, diarrhea/constipation, alopecia and edema; one Grade 5 ARDS/pneumonitis was related to trametinib. CONCLUSIONS Trametinib was associated with reduction in EHE-related pain and median PFS of more than 6 months providing palliative benefit in patients with advanced EHE, but the trial did not meet the ORR goal.
Collapse
Affiliation(s)
| | | | - Rachel Heise
- University of California, San Francisco, New York, NY, United States
| | | | | | | | | | - Edwin Choy
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States
| | | | - Gabriel Tinoco
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
| | - Angela Hirbe
- Washington University in St. Louis, saint louis, United States
| | - Ciara M Kelly
- Memorial Sloan Kettering Cancer Center, New York, NY, United States
| | - Steven Attia
- Mayo Clinic, Jacksonville, Florida, United States
| | | | - Gary K Schwartz
- Case Western Reserve University, Cleveland, OH, United States
| | | | | | | | - Erin Kozlowski
- Sarcoma Alliance for Research through Collaboration, United States
| | - Helen X Chen
- National Cancer Institute, Bethesda, MD, United States
| | | | - Brian P Rubin
- Cleveland Clinic and Lerner Research Institute, Cleveland, OH, United States
| |
Collapse
|
3
|
Gleason CE, Dickson MA, Klein (Dooley) ME, Antonescu CR, Gularte-Mérida R, Benitez M, Delgado JI, Kataru RP, Tan MWY, Bradic M, Adamson TE, Seier K, Richards AL, Palafox M, Chan E, D'Angelo SP, Gounder MM, Keohan ML, Kelly CM, Chi P, Movva S, Landa J, Crago AM, Donoghue MT, Qin LX, Serra V, Turkekul M, Barlas A, Firester DM, Manova-Todorova K, Mehrara BJ, Kovatcheva M, Tan NS, Singer S, Tap WD, Koff A. Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma. Clin Cancer Res 2024; 30:703-718. [PMID: 37695642 PMCID: PMC10870201 DOI: 10.1158/1078-0432.ccr-23-2378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 09/05/2023] [Accepted: 09/07/2023] [Indexed: 09/12/2023]
Abstract
PURPOSE We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans. PATIENTS AND METHODS We coordinated a first-in-kind phase II clinical trial of the CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma (DDLS) with cellular studies interrogating the molecular basis of geroconversion. RESULTS Thirty patients with progressing DDLS enrolled and were treated with 200 mg of abemaciclib twice daily. The median progression-free survival was 33 weeks at the time of the data lock, with 23 of 30 progression-free at 12 weeks (76.7%, two-sided 95% CI, 57.7%-90.1%). No new safety signals were identified. Concurrent preclinical work in liposarcoma cell lines identified ANGPTL4 as a necessary late regulator of geroconversion, the pathway from reversible cell-cycle exit to a stably arrested inflammation-provoking senescent cell. Using this insight, we were able to identify patients in which abemaciclib induced tumor cell senescence. Senescence correlated with increased leukocyte infiltration, primarily CD4-positive cells, within a month of therapy. However, those individuals with both senescence and increased TILs were also more likely to acquire resistance later in therapy. These suggest that combining senolytics with abemaciclib in a subset of patients may improve the duration of response. CONCLUSIONS Abemaciclib was well tolerated and showed promising activity in DDLS. The discovery of ANGPTL4 as a late regulator of geroconversion helped to define how CDK4/6i-induced cellular senescence modulates the immune tumor microenvironment and contributes to both positive and negative clinical outcomes. See related commentary by Weiss et al., p. 649.
Collapse
Affiliation(s)
- Caroline E. Gleason
- Louis V. Gerstner Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York
- Program in Molecular Biology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Mark A. Dickson
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Mary E. Klein (Dooley)
- Louis V. Gerstner Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York
- Program in Molecular Biology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | | | - Rodrigo Gularte-Mérida
- Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Marimar Benitez
- Louis V. Gerstner Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York
- Program in Molecular Biology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Juliana I. Delgado
- Louis V. Gerstner Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York
- Program in Molecular Biology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Raghu P. Kataru
- Department of Plastic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Mark Wei Yi Tan
- School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
| | - Martina Bradic
- The Marie Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Travis E. Adamson
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Kenneth Seier
- Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Allison L. Richards
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Marta Palafox
- The Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Eric Chan
- The Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sandra P. D'Angelo
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Mrinal M. Gounder
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Mary Louise Keohan
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Ciara M. Kelly
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Ping Chi
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
- Human Oncology and Pathogenesis, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sujana Movva
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Jonathan Landa
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Aimee M. Crago
- Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Mark T.A. Donoghue
- The Marie Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Li-Xuan Qin
- Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Violetta Serra
- The Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Mesruh Turkekul
- The Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Afsar Barlas
- The Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Daniel M. Firester
- Department of Sensory Neuroscience, The Rockefeller University, New York, New York
| | - Katia Manova-Todorova
- The Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Babak J. Mehrara
- Department of Plastic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Marta Kovatcheva
- Program in Molecular Biology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Nguan Soon Tan
- School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - Samuel Singer
- Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - William D. Tap
- Departments of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Andrew Koff
- Program in Molecular Biology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| |
Collapse
|
4
|
Kodosaki E, Daniels-Morgan A, Hassan N, Webb R, Morris K, Kelly CM. Development and characterisation of mgTHP-1, a novel in vitro model for neural macrophages with microglial characteristics. Neurol Res 2024; 46:1-13. [PMID: 37935114 DOI: 10.1080/01616412.2023.2257422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 04/23/2023] [Indexed: 11/09/2023]
Abstract
Neuroinflammation is primarily characterised by activation of the brain's resident macrophages - the microglia. However, other central nervous system (CNS) cells also contribute to this response, including the astrocytes and endothelial cells. In addition, there is infiltration into the CNS of peripherally derived immune cells. Together these cells mediate inflammation by the production of cytokines, chemokines, reactive oxygen species, and secondary messengers, and enacting of the appropriate response to those signals. However, deciphering the specific contributions of each cell type has been challenging. Studying CNS cell biology is often challenging, as the isolation of primary cells is not always feasible, and differentiation towards microglia-like cells is complex. Here, we demonstrate a novel method whereby THP-1 monocytic cells are differentiated into neural macrophage cells with microglia-like cell characteristics. The cells, designated mgTHP-1, show typical morphological and gene expression patterns of resident CNS macrophages and functionally respond to inflammatory stimuli by producing inflammatory cytokines. Furthermore, with the addition of Vicenin-2 (an anti-inflammatory flavonoid) such responses can be reversed. This novel cell model will allow further investigations, and hence insights, into the neuroinflammatory mechanisms associated with CNS diseases.
Collapse
Affiliation(s)
- E Kodosaki
- Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK
| | - A Daniels-Morgan
- Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK
| | - N Hassan
- Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK
| | - R Webb
- Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK
| | - K Morris
- Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK
| | - C M Kelly
- Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK
| |
Collapse
|
5
|
Kelly CM, Qin LX, Whiting KA, Richards AL, Avutu V, Chan JE, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Adamson T, Singer S, Bartlett EK, Crago AM, Yoon SS, Hwang S, Erinjeri JP, Antonescu CR, Tap WD, D’Angelo SP. A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma. Clin Cancer Res 2023; 29:2043-2051. [PMID: 36971773 PMCID: PMC10752758 DOI: 10.1158/1078-0432.ccr-22-3911] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 02/15/2023] [Accepted: 03/22/2023] [Indexed: 03/29/2023]
Abstract
PURPOSE Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor, proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined epacadostat with pembrolizumab, which has modest activity in select sarcoma subtypes. PATIENTS AND METHODS This phase II study enrolled patients with advanced sarcoma into five cohorts including (i) undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma, (ii) liposarcoma (LPS), (iii) leiomyosarcoma (LMS), (iv) vascular sarcoma, including angiosarcoma and epithelioid hemangioendothelioma (EHE), and (v) other subtypes. Patients received epacadostat 100 mg twice daily plus pembrolizumab at 200 mg/dose every 3 weeks. The primary endpoint was best objective response rate (ORR), defined as complete response (CR) and partial response (PR), at 24 weeks by RECIST v.1.1. RESULTS Thirty patients were enrolled [60% male; median age 54 years (range, 24-78)]. The best ORR at 24 weeks was 3.3% [PR, n = 1 (leiomyosarcoma); two-sided 95% CI, 0.1%-17.2%]. The median PFS was 7.6 weeks (two-sided 95% CI, 6.9-26.7). Treatment was well tolerated. Grade 3 treatment-related adverse events occurred in 23% (n = 7) of patients. In paired pre- and post-treatment tumor samples, no association was found between treatment and PD-L1 or IDO1 tumor expression or IDO-pathway-related gene expression by RNA sequencing. No significant changes in serum tryptophan or kynurenine levels were observed after baseline. CONCLUSIONS Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved.
Collapse
Affiliation(s)
- Ciara M. Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Li-Xuan Qin
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
| | - Karissa A. Whiting
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
| | - Allison L. Richards
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
| | - Viswatej Avutu
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Jason E. Chan
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Ping Chi
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Mark A. Dickson
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Mrinal M. Gounder
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Mary Louise Keohan
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Sujana Movva
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Benjamin A. Nacev
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Evan Rosenbaum
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Travis Adamson
- Department of Medicine, Memorial Sloan Kettering Cancer Center
| | - Sam Singer
- Department of Surgery, Memorial Sloan Kettering Cancer Center
| | | | - Aimee M. Crago
- Department of Surgery, Memorial Sloan Kettering Cancer Center
| | - Sam S. Yoon
- Department of Surgery, Memorial Sloan Kettering Cancer Center
| | - Sinchun Hwang
- Department of Radiology, Memorial Sloan Kettering Cancer Center
| | | | | | - William D. Tap
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
| | - Sandra P. D’Angelo
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Department of Medicine, Weill Cornell Medical College
- Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center
| |
Collapse
|
6
|
Dermawan JKT, Nafa K, Mohanty A, Xu Y, Rijo I, Casanova J, Villafania L, Benhamida J, Kelly CM, Tap WD, Boland PJ, Fabbri N, Healey JH, Ladanyi M, Lu C, Hameed M. Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma. Cancer Res Commun 2023; 3:431-443. [PMID: 36926116 PMCID: PMC10013202 DOI: 10.1158/2767-9764.crc-22-0397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 12/05/2022] [Accepted: 02/14/2023] [Indexed: 02/25/2023]
Abstract
Dedifferentiated chondrosarcoma (DDCS) is a rare high-grade chondrosarcoma characterized by a well-differentiated chondrosarcoma (WDCS) component that abruptly transitions to a high-grade, noncartilaginous sarcomatous component. To date, the molecular pathogenesis of DDCS and its distinction from conventional chondrosarcoma remain poorly understood. By targeted sequencing, we examined the mutational and copy-number profiles of 18 DDCS, including macrodissected WDCS components, compared with 55 clinically sequenced conventional chondrosarcomas. In conjunction with publicly available external data, we analyzed the methylation and expression profiles of 34 DDCS and 94 conventional chondrosarcomas. Isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 (IDH1/IDH2) mutations were present in 36% conventional chondrosarcomas and 71% DDCS. Compared with conventional chondrosarcomas, DDCS had higher frequencies of TP53 and TERT promoter mutations and CDKN2A/B copy-number losses. Paired analysis of macrodissected WDCS and the high-grade components revealed TERT promoter mutations as early events. Despite phenotypic similarities, the percentage of genome with copy-number alterations in DDCS was significantly lower than that in other high-grade sarcomas. Differential methylation analysis revealed reduction of IDH1/IDH2-associated global hypermethylation characteristically seen in conventional chondrosarcoma and a distinct methylation profile in DDCS. The WDCS and high-grade components in DDCS showed similar methylation profiles. These CpG sites were associated with upregulated expression of genes involved in G2-M checkpoints and E2F targets. Genomic profiling revealed enrichment of TP53, TERT promoter, and CDKN2A/B alterations in DDCS. Integrated methylation and gene expression analysis revealed distinct IDH1/IDH2-associated methylation and transcriptional profiles as early events in DDCS, which may underlie the pathogenesis of dedifferentiation in chondrosarcomas. Significance DDCS is a rare, high-grade chondrosarcoma with a dismal prognosis. About 50%-80% of DDCS harbor IDH1/IDH2 mutations. We uncover a significant alteration of IDH-associated methylation profile in DDCS, which we propose is key to the progression to dedifferentiation. In this context, the potential effect of the use of IDH inhibitors is unclear but important to address, as clinical trials of selective IDH1 inhibitors showed worse outcome in DDCS.
Collapse
Affiliation(s)
- Josephine Kam Tai Dermawan
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Khedoujia Nafa
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Abhinita Mohanty
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Yingjuan Xu
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ivelise Rijo
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jacklyn Casanova
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Liliana Villafania
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jamal Benhamida
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ciara M. Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - William D. Tap
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Patrick J. Boland
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Nicola Fabbri
- Department of Orthopedic Surgery, New York University Grossman School of Medicine, New York, New York
| | - John H. Healey
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Marc Ladanyi
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Chao Lu
- Department of Genetics and Development, Columbia University Medical Center, New York, New York
| | - Meera Hameed
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
7
|
von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Poppe M, Schuetze S, Shabason J, Spraker MB, Zimel M, Bergman MA, Sundar H, Hang LE. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw 2022; 20:1204-1214. [PMID: 36351335 PMCID: PMC10245542 DOI: 10.6004/jnccn.2022.0058] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.
Collapse
Affiliation(s)
| | | | | | | | - Seth M Pollack
- 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University
| | | | | | | | - Edwin Choy
- 9Massachusetts General Hospital Cancer Center
| | - Mary Connelly
- 10The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
| | - Sarah Dry
- 11UCLA Jonsson Comprehensive Cancer Center
| | | | | | | | - Jade Homsi
- 14UT Southwestern Simmons Comprehensive Cancer Center
| | | | | | | | - David Liebner
- 10The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
| | | | | | - Nathan W Mesko
- 20Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
| | - Christian Meyer
- 21The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
| | - Alberto S Pappo
- 22St. Jude Children's Research Hospital/University of Tennessee Health Science Center
| | | | | | - Matthew Poppe
- 25Huntsman Cancer Institute at the University of Utah
| | | | - Jacob Shabason
- 27Abramson Cancer Center at the University of Pennsylvania
| | - Matthew B Spraker
- 28Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
| | - Melissa Zimel
- 29UCSF Helen Diller Family Comprehensive Cancer Center; and
| | | | | | | |
Collapse
|
8
|
Wong MK, Burgess M, Chandra S, Schadendorf D, Silk A, Olszanski AJ, Grob JJ, Jang S, Grewal JS, Lewis KD, Fecher L, Rabinowits G, Lebbe C, Martin-Liberal J, Di Giacomo AM, Friedlander P, Brohl AS, Croft B, McGreivy JS, Rothbaum WP, Hanna GJ, Kelly CM. Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53 Merkel cell carcinoma (MCC). J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.08.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Chen W, Bhatia S, Brohl AS, Chandra S, Dakhil S, Fecher LA, Gao L, Gooley TA, Hanna GJ, Hibbert R, Kelly CM, Kiriluk SM, Lewis K, Moschos S, Nghiem P, Thompson JA, Tykodi SS. ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Lee JS, Kelly CM, Bartlett EK. Management of pelvic sarcoma. Eur J Surg Oncol 2022; 48:2299-2307. [PMID: 36195471 DOI: 10.1016/j.ejso.2022.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 09/07/2022] [Accepted: 09/14/2022] [Indexed: 10/14/2022] Open
Abstract
Pelvic sarcomas are a rare and heterogenous group of tumors divided into two groups: soft tissue sarcomas and bone sarcomas. Soft tissue sarcomas of the pelvis include most commonly liposarcoma, leiomyosarcoma, gastrointestinal stromal tumors, malignant peripheral nerve sheath tumors, and solitary fibrous tumors. Bone sarcomas of the pelvis most commonly include osteosarcoma and chondrosarcoma. Multidisciplinary treatment at a center experienced in the treatment of sarcoma is essential. Management is dictated by histologic type and grade. Surgical resection with wide margins is the cornerstone of treatment for pelvic sarcomas, although this is often challenging due to anatomic constraints of the pelvis. Multimodal treatment is critical due to the high risk of local recurrence in the pelvis.
Collapse
Affiliation(s)
- Jay S Lee
- Department of Surgery, Duke University, Durham, NC, USA
| | - Ciara M Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Edmund K Bartlett
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
| |
Collapse
|
11
|
von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Pollack SM, Poppe M, Riedel RF, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Hang LE, Sundar H, Bergman MA. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20:815-833. [PMID: 35830886 PMCID: PMC10186762 DOI: 10.6004/jnccn.2022.0035] [Citation(s) in RCA: 81] [Impact Index Per Article: 40.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.
Collapse
Affiliation(s)
| | | | | | | | | | - Edwin Choy
- Massachusetts General Hospital Cancer Center
| | - Mary Connelly
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
| | - Sarah Dry
- UCLA Jonsson Comprehensive Cancer Center
| | | | | | | | - Jade Homsi
- UT Southwestern Simmons Comprehensive Cancer Center
| | | | | | - Edward Kim
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
| | - David Liebner
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
| | | | | | - Nathan W Mesko
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
| | - Christian Meyer
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
| | - Alberto S Pappo
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
| | | | | | - Seth M Pollack
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
| | | | | | | | - Jacob Shabason
- Abramson Cancer Center at the University of Pennsylvania
| | | | - Matthew B Spraker
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
| | - Melissa Zimel
- UCSF Helen Diller Family Comprehensive Cancer Center; and
| | | | | | | |
Collapse
|
12
|
Nacev BA, Sanchez-Vega F, Smith SA, Antonescu CR, Rosenbaum E, Shi H, Tang C, Socci ND, Rana S, Gularte-Mérida R, Zehir A, Gounder MM, Bowler TG, Luthra A, Jadeja B, Okada A, Strong JA, Stoller J, Chan JE, Chi P, D'Angelo SP, Dickson MA, Kelly CM, Keohan ML, Movva S, Thornton K, Meyers PA, Wexler LH, Slotkin EK, Glade Bender JL, Shukla NN, Hensley ML, Healey JH, La Quaglia MP, Alektiar KM, Crago AM, Yoon SS, Untch BR, Chiang S, Agaram NP, Hameed MR, Berger MF, Solit DB, Schultz N, Ladanyi M, Singer S, Tap WD. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nat Commun 2022; 13:3405. [PMID: 35705560 PMCID: PMC9200818 DOI: 10.1038/s41467-022-30453-x] [Citation(s) in RCA: 54] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Accepted: 05/02/2022] [Indexed: 02/02/2023] Open
Abstract
The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or a few subtypes. Herein, we report a comparative genetic analysis of 2,138 sarcomas representing 45 pathological entities. This cohort is prospectively analyzed using targeted sequencing to characterize subtype-specific somatic alterations in targetable pathways, rates of whole genome doubling, mutational signatures, and subtype-agnostic genomic clusters. The most common alterations are in cell cycle control and TP53, receptor tyrosine kinases/PI3K/RAS, and epigenetic regulators. Subtype-specific associations include TERT amplification in intimal sarcoma and SWI/SNF alterations in uterine adenosarcoma. Tumor mutational burden, while low compared to other cancers, varies between and within subtypes. This resource will improve sarcoma models, motivate studies of subtype-specific alterations, and inform investigations of genetic factors and their correlations with treatment response.
Collapse
Affiliation(s)
- Benjamin A Nacev
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
- The Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, 10065, NY, USA
| | - Francisco Sanchez-Vega
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Shaleigh A Smith
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Cristina R Antonescu
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Evan Rosenbaum
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Hongyu Shi
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Cerise Tang
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Physiology, Biophysics and Systems Biology Graduate Program, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Nicholas D Socci
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Bioinformatics Core, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Satshil Rana
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | | | - Ahmet Zehir
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Mrinal M Gounder
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Timothy G Bowler
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Anisha Luthra
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Bhumika Jadeja
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Azusa Okada
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Jonathan A Strong
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Jake Stoller
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Jason E Chan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Ping Chi
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Sandra P D'Angelo
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Mark A Dickson
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Ciara M Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Mary Louise Keohan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Sujana Movva
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Katherine Thornton
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Paul A Meyers
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Leonard H Wexler
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Emily K Slotkin
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Julia L Glade Bender
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Neerav N Shukla
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Martee L Hensley
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
| | - John H Healey
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Michael P La Quaglia
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Surgery, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Kaled M Alektiar
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Aimee M Crago
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Surgery, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Sam S Yoon
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Surgery, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Brian R Untch
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Surgery, Weill Cornell Medical College, New York, 10065, NY, USA
| | - Sarah Chiang
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Narasimhan P Agaram
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Meera R Hameed
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Michael F Berger
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - David B Solit
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Nikolaus Schultz
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Marc Ladanyi
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA
| | - Samuel Singer
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA.
- Department of Surgery, Weill Cornell Medical College, New York, 10065, NY, USA.
| | - William D Tap
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA.
- Department of Medicine, Weill Cornell Medical College, New York, 10065, NY, USA.
| |
Collapse
|
13
|
Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SPD, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DX. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun 2022; 13:3406. [PMID: 35705558 PMCID: PMC9200814 DOI: 10.1038/s41467-022-30496-0] [Citation(s) in RCA: 46] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 05/04/2022] [Indexed: 02/07/2023] Open
Abstract
There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas' molecular drivers. Through targeted panel sequencing of 7494 sarcomas representing 44 histologies, we identify highly recurrent and type-specific alterations that aid in diagnosis and treatment decisions. Sequencing could lead to refinement or reassignment of 10.5% of diagnoses. Nearly one-third of patients (31.7%) harbor potentially actionable alterations, including a significant proportion (2.6%) with kinase gene rearrangements; 3.9% have a tumor mutational burden ≥10 mut/Mb. We describe low frequencies of microsatellite instability (<0.3%) and a high degree of genome-wide loss of heterozygosity (15%) across sarcomas, which are not readily explained by homologous recombination deficiency (observed in 2.5% of cases). In a clinically annotated subset of 118 patients, we validate actionable genetic events as therapeutic targets. Collectively, our findings reveal the genetic landscape of human sarcomas, which may inform future development of therapeutics and improve clinical outcomes for patients with these rare cancers.
Collapse
Affiliation(s)
- Mrinal M Gounder
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Weill Cornell Medical College, New York, NY, USA.
| | | | | | | | - Richard A Ferraro
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | | | - Anita Krishnan
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Jessica Lee
- Foundation Medicine, Inc., Cambridge, MA, USA
| | | | - Wassim Abida
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Alexander Drilon
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Ping Chi
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Sandra P D' Angelo
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Mark A Dickson
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Mary Lou Keohan
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Ciara M Kelly
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | | | - Sant P Chawla
- Sarcoma Center of Santa Monica, Santa Monica, CA, USA
| | - Edwin Choy
- Massachusetts General Hospital, Cambridge, MA, USA
- Harvard Medical School, Boston, MA, USA
| | | | - Christian F Meyer
- Johns Hopkins Sidney Kimmel Comprehensive Center, Baltimore, MD, USA
| | - Parvathi A Myer
- Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
| | | | - Ross A Okimoto
- University of California at San Francisco, San Francisco, CA, USA
| | | | - Vinod Ravi
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Arun S Singh
- University of California at Los Angeles, Los Angeles, CA, USA
| | - Neeta Somaiah
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Andrew J Wagner
- Harvard Medical School, Boston, MA, USA
- Dana-Farber Cancer Institute, Boston, MA, USA
| | - John H Healey
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | | | | | - Jeffrey S Ross
- Foundation Medicine, Inc., Cambridge, MA, USA
- Albany Medical College, Albany, NY, USA
| | - Marc Ladanyi
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Samuel Singer
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Murray F Brennan
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Gary K Schwartz
- Herbert Irving Cancer Center, Columbia University, New York, NY, USA
| | | | - David M Thomas
- Garvan Institute of Medical Research, Darlinghurst,, NSW, Australia
| | - Robert G Maki
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - William D Tap
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medical College, New York, NY, USA
| | - Siraj M Ali
- Foundation Medicine, Inc., Cambridge, MA, USA
| | | |
Collapse
|
14
|
Chi P, Qin LX, Camacho N, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Francis JH, Martindale M, Phelan HT, Biniakewitz MD, Lee CJ, Singer S, Hwang S, Berger MF, Chen Y, Antonescu CR, Tap WD. Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clin Cancer Res 2022; 28:1507-1517. [PMID: 35110417 PMCID: PMC9012681 DOI: 10.1158/1078-0432.ccr-21-3909] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 01/06/2022] [Accepted: 01/31/2022] [Indexed: 01/07/2023]
Abstract
PURPOSE This phase Ib trial was designed to evaluate the safety and early efficacy signal of the combination of imatinib and binimetinib in patients with imatinib-resistant advanced gastrointestinal stromal tumors (GISTs). PATIENTS AND METHODS This trial used a standard 3 + 3 design to determine the recommended phase II dose (RP2D). Additional patients were enrolled on an expansion cohort at the RP2D enriching for succinate dehydrogenase (SDH)-deficient GISTs to explore potential efficacy. RESULTS The trial enrolled nine patients in the dose-escalation cohort and 14 in the dose-expansion cohort including six with SDH-deficient GISTs. Imatinib 400 mg daily with binimetinib 45 mg twice daily was established as the RP2D. Dose-limiting toxicity (DLT) was asymptomatic grade 4 creatinine phosphokinase (CPK) elevation. The most common non-DLT grade 3/4 toxicity was asymptomatic CPK elevation (69.6%). Other common ≥grade 2 toxicities included peripheral edema (17.4%), acneiform rash (21.7%), anemia (30.4%), hypophosphatemia (39.1%), and aspartate aminotransferase (AST) increase (17.4%). Two serious adverse events occurred (grade 2 dropped head syndrome and grade 3 central retinal vein occlusion). No unexpected toxicities were observed. Limited clinical activity was observed in KIT-mutant GIST. For SDH-deficient GISTs, one of five had confirmed RECIST1.1 partial response (PR). The median progression-free survival (mPFS) in patients with SDH-deficient GIST was 45.1 months [95% confidence interval (CI), 15.8-not estimable (NE)]; the median overall survival (mOS) was not reached (95% CI, 31.6 months-NE). One patient with a refractory metastatic SDH-deficient GIST had an exceptional pathologic response and durable clinical benefit. CONCLUSIONS The combination of imatinib and binimetinib is safe with manageable toxicity and has encouraging activity in SDH-deficient but not imatinib-refractory KIT/PDGFRA-mutant GISTs. The observed clinical benefits provide a motivation for a larger trial of the combination strategy in SDH-deficient GISTs.
Collapse
Affiliation(s)
- Ping Chi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Li-Xuan Qin
- Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Niedzica Camacho
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ciara M. Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Sandra P. D'Angelo
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Mark A. Dickson
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Mrinal M. Gounder
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Mary L. Keohan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Sujana Movva
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Benjamin A. Nacev
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Evan Rosenbaum
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Katherine A. Thornton
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Aimee M. Crago
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Surgery, Weill Cornell Medical College, New York, New York
| | - Jasmine H. Francis
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Ophthalmology, Weill Cornell Medical College, New York, New York
| | - Moriah Martindale
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Haley T. Phelan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Cindy J. Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Samuel Singer
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Surgery, Weill Cornell Medical College, New York, New York
| | - Sinchun Hwang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Michael F. Berger
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Yu Chen
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | | | - William D. Tap
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| |
Collapse
|
15
|
Rosenbaum E, Antonescu CR, Smith S, Bradic M, Kashani D, Richards AL, Donoghue M, Kelly CM, Nacev B, Chan JE, Chi P, Dickson MA, Keohan ML, Gounder MM, Movva S, Avutu V, Thornton K, Zehir A, Bowman AS, Singer S, Tap W, D'Angelo S. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. J Immunother Cancer 2022; 10:jitc-2021-004149. [PMID: 35365586 PMCID: PMC8977792 DOI: 10.1136/jitc-2021-004149] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/12/2022] [Indexed: 12/15/2022] Open
Abstract
Background Angiosarcoma is a histologically and molecularly heterogeneous vascular neoplasm with aggressive clinical behavior. Emerging data suggests that immune checkpoint blockade (ICB) is efficacious against some angiosarcomas, particularly cutaneous angiosarcoma of the head and neck (CHN). Methods Patients with histologically confirmed angiosarcoma treated with ICB-based therapy at a comprehensive cancer center were retrospectively identified. Clinical characteristics and the results of targeted exome sequencing, transcriptome sequencing, and immunohistochemistry analyses were examined for correlation with clinical benefit. Durable clinical benefit was defined as a progression-free survival (PFS) of ≥16 weeks. Results For the 35 patients included in the analyses, median PFS and median overall survival (OS) from the time of first ICB-based treatment were 11.9 (95% CI 7.4 to 31.9) and 42.5 (95% CI 19.6 to 114.2) weeks, respectively. Thirteen patients (37%) had PFS ≥16 weeks. Clinical factors associated with longer PFS and longer OS in multivariate analyses were ICB plus other therapy regimens, CHN disease, and white race. Three of 10 patients with CHN angiosarcoma evaluable for tumor mutational burden (TMB) had a TMB ≥10. Five of six patients with CHN angiosarcoma evaluable for mutational signature analysis had a dominant mutational signature associated with ultraviolet (UV) light. No individual gene or genomic pathway was significantly associated with PFS or OS; neither were TMB or UV signature status. Analyses of whole transcriptomes from nine patient tumor samples found upregulation of angiogenesis, inflammatory response, and KRAS signaling pathways, among others, in patients with PFS ≥16 weeks, as well as higher levels of cytotoxic T cells, dendritic cells, and natural killer cells. Patients with PFS <16 weeks had higher numbers of cancer-associated fibroblasts. Immunohistochemistry findings for 12 patients with baseline samples available suggest that neither PD-L1 expression nor presence of tumor-infiltrating lymphocytes at baseline appears necessary for a response to ICB-based therapy. Conclusions ICB-based therapy benefits only a subset of angiosarcoma patients. Patients with CHN angiosarcoma are more likely to have PFS ≥16 weeks, a dominant UV mutational signature, and higher TMB than angiosarcomas arising from other primary sites. However, clinical benefit was seen in other angiosarcomas also and was not restricted to tumors with a high TMB, a dominant UV signature, PD-L1 expression, or presence of tumor infiltrating lymphocytes at baseline.
Collapse
Affiliation(s)
- Evan Rosenbaum
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA .,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Cristina R Antonescu
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Shaleigh Smith
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Martina Bradic
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Daniel Kashani
- Department of Medicine, SUNY Downstate Medical Center, New York City, New York, USA
| | - Allison L Richards
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Mark Donoghue
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Ciara M Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Benjamin Nacev
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Jason E Chan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Ping Chi
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Mark A Dickson
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Mary L Keohan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Mrinal M Gounder
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Sujana Movva
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Viswatej Avutu
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Katherine Thornton
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Ahmet Zehir
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Anita S Bowman
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Samuel Singer
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - William Tap
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Sandra D'Angelo
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York City, New York, USA
| |
Collapse
|
16
|
Chi P, Qin LX, Nguyen B, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. J Clin Oncol 2022; 40:997-1008. [PMID: 35041493 PMCID: PMC8937014 DOI: 10.1200/jco.21.02029] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 11/30/2021] [Accepted: 12/14/2021] [Indexed: 01/13/2023] Open
Abstract
PURPOSE Dual targeting of the gastrointestinal stromal tumor (GIST) lineage-specific master regulators, ETV1 and KIT, by MEK and KIT inhibitors were synergistic preclinically and may enhance clinical efficacy. This trial was designed to test the efficacy and safety of imatinib plus binimetinib in first-line treatment of GIST. METHODS In this trial (NCT01991379), treatment-naive adult patients with confirmed advanced GISTs received imatinib (400 mg once daily) plus binimetinib (30 mg twice daily), 28-day cycles. The primary end point was RECIST1.1 best objective response rate (ORR; complete response plus partial response [PR]). The study was designed to detect a 20% improvement in the ORR over imatinib alone (unacceptable rate of 45%; acceptable rate of 65%), using an exact binomial test, one-sided type I error of 0.08 and type II error of 0.1, and a planned sample size of 44 patients. Confirmed PR or complete response in > 24 patients are considered positive. Secondary end points included Choi and European Organisation for Research and Treatment of Cancer Response Rate, progression-free survival (PFS), overall survival (OS), pathologic responses, and toxicity. RESULTS Between September 15, 2014, and November 15, 2020, 29 of 42 evaluable patients with advanced GIST had confirmed RECIST1.1 PR. The best ORR was 69.0% (two-sided 95% CI, 52.9 to 82.4). Thirty-nine of 41 (95.1%) had Choi PR approximately 8 weeks. Median PFS was 29.9 months (95% CI, 24.2 to not estimable); median OS was not reached (95% CI, 50.4 to not estimable). Five of eight patients with locally advanced disease underwent surgery after treatment and achieved significant pathologic response (≥ 90% treatment effect). There were no unexpected toxicities. Grade 3 and 4 toxicity included asymptomatic creatinine phosphokinase elevation (79.1%), hypophosphatemia (14.0%), neutrophil decrease (9.3%), maculopapular rash (7.0%), and anemia (7.0%). CONCLUSION The study met the primary end point. The combination of imatinib and binimetinib is effective with manageable toxicity and warrants further evaluation in direct comparison with imatinib in frontline treatment of GIST.
Collapse
Affiliation(s)
- Ping Chi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Li-Xuan Qin
- Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Bastien Nguyen
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
- Marie-José and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Ciara M. Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Sandra P. D'Angelo
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Mark A. Dickson
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Mrinal M. Gounder
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Mary L. Keohan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Sujana Movva
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Benjamin A. Nacev
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Evan Rosenbaum
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Katherine A. Thornton
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Aimee M. Crago
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Surgery, Weill Cornell Medical College, New York, NY
| | - Sam Yoon
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Surgery, Weill Cornell Medical College, New York, NY
| | - Gary Ulaner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
- Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA
| | - Randy Yeh
- Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA
| | - Moriah Martindale
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Haley T. Phelan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Sarah Warda
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Cindy J. Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Michael F. Berger
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
- Marie-José and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Nikolaus D. Schultz
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
- Marie-José and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Samuel Singer
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Surgery, Weill Cornell Medical College, New York, NY
| | - Sinchun Hwang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Yu Chen
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| | | | - William D. Tap
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Medicine, Weill Cornell Medical College, New York, NY
| |
Collapse
|
17
|
Affiliation(s)
| | - Karina Nielsen
- Institute of Work Psychology, The University of Sheffield, Sheffield, UK
| | | | - Ciara M. Kelly
- Institute of Work Psychology, The University of Sheffield, Sheffield, UK
| |
Collapse
|
18
|
Schoenfeld JD, Agaram NP, Lefkowitz RA, Kelly CM, Healey JH, Gounder MM. OUP accepted manuscript. Oncologist 2022; 27:e294-e296. [PMID: 35274715 PMCID: PMC8914480 DOI: 10.1093/oncolo/oyab050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Accepted: 11/05/2021] [Indexed: 11/14/2022] Open
Abstract
Palmar and plantar fibromatosis are benign proliferative processes which present as a diffuse thickening or nodules of the hands and/or feet and may lead to flexion contractures, pain, and functional impairment known as Dupuytren and Ledderhose diseases, respectively. Current treatments are noncurative and associated with significant morbidity. Here, we report on the outcomes of 5 patients with advanced disease, no longer surgical candidates, treated with sorafenib. Sorafenib exhibited an expected safety profile. All 5 patients demonstrated objective responses as evaluated by a decrease in tumor size and/or tumor cellularity from baseline and all 5 patients reported subjective pain relief and/or functional improvement. Mechanistically, immunohistochemistry revealed patchy positivity for PDGFRβ, a known target of sorafenib. The outcomes of these 5 patients suggest the safety and efficacy of a relatively well-tolerated oral agent in the treatment of Dupuytren and Ledderhose diseases and suggest the need for future controlled studies.
Collapse
Affiliation(s)
- Joshua D Schoenfeld
- Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
| | - Narasimhan P Agaram
- Department of Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
| | - Robert A Lefkowitz
- Department of Radiology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
| | - Ciara M Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
| | - John H Healey
- Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
| | - Mrinal M Gounder
- Corresponding author: Mrinal M. Gounder, MD, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
| |
Collapse
|
19
|
Klemen ND, Hwang S, Bradic M, Rosenbaum E, Dickson MA, Gounder MM, Kelly CM, Keohan ML, Movva S, Thornton KA, Chi P, Nacev BA, Chan JE, Bartlett EK, Richards AL, Singer S, Donoghue MTA, Tap WD, D'Angelo SP. Long term follow-up and patterns of response, progression and hyperprogression in patients after PD-1 blockade in advanced sarcoma. Clin Cancer Res 2021; 28:939-947. [PMID: 34965948 DOI: 10.1158/1078-0432.ccr-21-3445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Revised: 11/23/2021] [Accepted: 12/22/2021] [Indexed: 11/16/2022]
Abstract
PURPOSE PD-1 blockade can mediate objective responses in advanced sarcomas, but their durability has not been established and it is unclear if hyperprogressive disease (HPD) occurs in sarcomas treated with PD-1 inhibitors. METHODS We pooled patients who were treated prospectively with nivolumab or pembrolizumab as monotherapy or with bempegaldesleukin, epacadostat, ipilimumab or Talimogene laherparepvec. We did a new independent assessment for HPD and analyzed clinical, pathologic and genomic data from baseline tumor biopsies. Our primary endpoint was the incidence of HPD; secondary endpoints were clinical or genomic correlates of response or HPD. RESULTS We treated 134 patients with advanced sarcoma from 2015 - 2019. Twenty-one patients (16%) had a complete or partial response (CR/PR), and 30% of responses were durable for over 2 years. Forty-eight (36%) patients had stable disease (SD), 45 (34%) had progressive disease without HPD (PD) and 15 (11%) had HPD. Five patients (4%) were not evaluable for HPD. The sarcoma subtypes, sites of metastasis, clinical course, and genomic alterations in patients with PD and HPD were similar, except HPD tumors were smaller at baseline. CONCLUSIONS In patients with advanced sarcoma, PD-1 blockade can mediate durable responses. HPD occurs in sarcoma at an incidence that is similar to what has been reported in other solid tumors, but patients with HPD were clinically and biologically similar to those who had PD. Further research is required to establish whether HPD is a biologically distinct phenomenon and whether a theoretical risk of HPD should influence patient management.
Collapse
Affiliation(s)
| | | | - Martina Bradic
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
| | | | - Mark A Dickson
- Department of Medicine, Memorial Sloan Kettering Cancer Center
| | - Mrinal M Gounder
- Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
| | | | | | | | | | - Ping Chi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
| | | | - Jason E Chan
- Medicine, Memorial Sloan Kettering Cancer Center
| | | | - Allison L Richards
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
| | | | - Mark T A Donoghue
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
| | - William D Tap
- Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
| | - Sandra P D'Angelo
- Medicine, Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
| |
Collapse
|
20
|
Nolan K, O'Donnell K, Moloney FJ, Kelly CM, Potter S. The impact of a See and Treat Clinic on skin cancer treatment time. J Plast Reconstr Aesthet Surg 2021; 75:893-939. [PMID: 34840112 DOI: 10.1016/j.bjps.2021.11.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 10/30/2021] [Accepted: 11/07/2021] [Indexed: 11/25/2022]
Affiliation(s)
- K Nolan
- Department of Plastic and Reconstructive Surgery, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - K O'Donnell
- Department of Plastic and Reconstructive Surgery, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - F J Moloney
- Department of Dermatology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland; Mater Melanoma Group, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - C M Kelly
- Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland; Mater Melanoma Group, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - S Potter
- Department of Plastic and Reconstructive Surgery, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland; Mater Melanoma Group, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland.
| |
Collapse
|
21
|
Bartlett EK, D'Angelo SP, Kelly CM, Siegelbaum RH, Fisher C, Antonescu CR, Ariyan CE. Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases. Front Oncol 2021; 11:725484. [PMID: 34722269 PMCID: PMC8554327 DOI: 10.3389/fonc.2021.725484] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 09/24/2021] [Indexed: 12/30/2022] Open
Abstract
Treatment options for patients with advanced sarcoma remain limited. Promising responses to checkpoint inhibition have been observed, but responses to single-agent PD-1 inhibition are rare. We report on two patients with multiply recurrent myxofibrosarcoma treated with the combination of regionally administered melphalan (via isolated limb infusion) and pembrolizumab. Both patients had recurrent disease after multiple surgical resections and radiation. Analysis of primary tumors demonstrated microsatellite stable tumors with few mutations. After combination treatment, one patient had a significant partial response of 6 months duration, the second patient had a complete response of 2 years duration. Post treatment biopsies demonstrated immune infiltration into the tumor. These promising responses in patients with multiply recurrent myxofibrosarcoma have prompted the development of an investigator-initiated clinical trial to formally study the combination of regional melphalan and pembrolizumab in a systematic fashion (NCT04332874).
Collapse
Affiliation(s)
- Edmund K Bartlett
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.,Department of Surgery, Weill Cornell Medical College, New York, NY, United States
| | - Sandra P D'Angelo
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.,Department of Medicine, Weill Cornell Medical College, New York, NY, United States
| | - Ciara M Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.,Department of Medicine, Weill Cornell Medical College, New York, NY, United States
| | - Robert H Siegelbaum
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.,Department of Radiology, Weill Cornell Medical College, New York, NY, United States
| | - Charles Fisher
- Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
| | - Cristina R Antonescu
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
| | - Charlotte E Ariyan
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.,Department of Surgery, Weill Cornell Medical College, New York, NY, United States
| |
Collapse
|
22
|
Lee A, Kang JJ, Bernstein H, Marqueen KE, Neal B, Kelly CM, Dickson MA, Jillian Tsai C, Tap W, Singer S, Alektiar K, Lee NY. Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Med 2021; 10:4221-4227. [PMID: 34085781 PMCID: PMC8267151 DOI: 10.1002/cam4.3646] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 11/10/2020] [Accepted: 11/12/2020] [Indexed: 01/25/2023] Open
Abstract
Patients with previously treated, recurrent or metastatic sarcomas who have progressed on multiples lines of systemic therapy may have limited options for local control. We evaluated outcomes of palliative proton therapy with the quad shot regimen to unresectable disease for patients with recurrent and/or metastatic sarcoma. From 2014 to 2018, 28 patients with recurrent or metastatic sarcomas were treated to 40 total sites with palliative proton RT with quad shot (14.8 Gy/4 twice daily). Outcomes included toxicity, ability to receive further systemic therapy, and subjective palliative response. Univariate analysis was performed for local progression‐free survival (LPFS) and overall survival (OS). Of the 40 total sites, 25 (62.5%) received ≥3 cycles with median follow up of 12 months (IQR 4–19). The most common histologies were GIST (9; 22.5%) and leiomyosarcoma (7; 17.5%). A total of 27 (67.5%) sites were located in the abdomen or pelvis. Seventeen (42.5%) treatments involved concurrent systemic therapy and 13 (32.5%) patients received further systemic therapy following proton therapy. Overall subjective palliative response was 70%. Median LPFS was 11 months and 6‐month LPFS was 66.1%. On univariate analysis, receipt of four cycles of quad shot (HR 0.06, p = 0.02) and receipt of systemic therapy after completion of radiation therapy (HR 0.17, p = 0.02) were associated with improved LPFS. Three grade 3 acute toxicities were observed. The proton quad shot regimen serves as a feasible alternative for patients with previously treated, recurrent or metastatic sarcomas where overall treatment options may be limited.
Collapse
Affiliation(s)
- Anna Lee
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.,Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Jung J Kang
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Havah Bernstein
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Kathryn E Marqueen
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.,Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Brian Neal
- ProCure Proton Therapy Center, Somerset, NJ, USA
| | - Ciara M Kelly
- Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Department of Medicine, Weill Cornell Medical College, New York, NY, USA
| | - Mark A Dickson
- Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Department of Medicine, Weill Cornell Medical College, New York, NY, USA
| | - Chiaojung Jillian Tsai
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - William Tap
- Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Department of Medicine, Weill Cornell Medical College, New York, NY, USA
| | - Samuel Singer
- Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Department of Surgery, Weill Cornell Medical College, New York, NY, USA
| | - Kaled Alektiar
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Nancy Y Lee
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
23
|
Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol 2021; 14:2. [PMID: 33402214 PMCID: PMC7786896 DOI: 10.1186/s13045-020-01026-6] [Citation(s) in RCA: 103] [Impact Index Per Article: 34.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 12/15/2020] [Indexed: 02/07/2023] Open
Abstract
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or PDGFRα. Determination of the GIST molecular subtype upon diagnosis is important because this information informs therapeutic decisions in both the adjuvant and metastatic setting. The management of GIST was revolutionized by the introduction of imatinib, a KIT inhibitor, which has become the standard first line treatment for metastatic GIST. However, despite a clinical benefit rate of 80%, the majority of patients with GIST experience disease progression after 2-3 years of imatinib therapy. Second and third line options include sunitinib and regorafenib, respectively, and yield low response rates and limited clinical benefit. There have been recent FDA approvals for GIST including ripretinib in the fourth-line setting and avapritinib for PDGFRA exon 18-mutant GIST. This article aims to review the optimal treatment approach for the management of patients with advanced GIST. It examines the standard treatment options available but also explores the novel treatment approaches in the setting of imatinib refractory GIST.
Collapse
Affiliation(s)
- Ciara M. Kelly
- grid.51462.340000 0001 2171 9952Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA ,grid.5386.8000000041936877XDepartment of Medicine, Weill Cornell Medical College, New York, USA
| | - Laura Gutierrez Sainz
- grid.81821.320000 0000 8970 9163Department of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Ping Chi
- grid.51462.340000 0001 2171 9952Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA ,grid.5386.8000000041936877XDepartment of Medicine, Weill Cornell Medical College, New York, USA ,grid.51462.340000 0001 2171 9952Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
| |
Collapse
|
24
|
Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R, Ahmad H, Biniakewitz M, Condy M, Phelan H, Callahan M, Wong P, Singer S, Ariyan C, Bartlett EK, Crago A, Yoon S, Hwang S, Erinjeri JP, Qin LX, Tap WD, D'Angelo SP. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA Oncol 2020; 6:402-408. [PMID: 31971541 DOI: 10.1001/jamaoncol.2019.6152] [Citation(s) in RCA: 107] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Importance Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming. Objective To examine whether T-VEC in combination with pembrolizumab is associated with increased tumor-infiltrating lymphocyte infiltration and programmed death-ligand 1 expression and thus with increased antitumor activity in patients with locally advanced or metastatic sarcoma. Design, Setting, and Participants This open-label, single-institution phase 2 interventional trial of T-VEC plus pembrolizumab enrolled 20 patients with locally advanced or metastatic sarcoma between March 16 and December 4, 2017, for whom at least 1 standard systemic therapy had failed. The median duration of therapy was 16 weeks (range, 7-67 weeks). Reported analyses include data through December 14, 2018. Intervention Patients received pembrolizumab (200-mg flat dose) intravenously and T-VEC (first dose, ≤4 mL × 106 plaque-forming units [PFU]/mL; second and subsequent doses, ≤4 mL × 108 PFU/mL) injected into palpable tumor site(s) on day 1 of each 21-day cycle. Main Outcomes and Measures The primary end point was objective response rate (ORR; complete response and partial response) at 24 weeks determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, criteria. Secondary end points included best ORR by immune-related RECIST criteria, progression-free survival rate at 24 weeks, overall survival, and safety. Results All 20 patients (12 women [60%]; median age, 63.5 years [range, 24-90 years]) were evaluable for response. The study met its primary end point of evaluating the best ORR at 24 weeks determined by RECIST, version 1.1, criteria; the best ORR was 30% (95% CI, 12%-54%; n = 6). The ORR overall was 35% (95% CI, 15%-59%; n = 7). The incidence of grade 3 treatment-related adverse events was low (4 patients [20%]). There were no grade 4 treatment-related adverse events or treatment-related deaths. Conclusions and Relevance In this phase 2 clinical trial, treatment with T-VEC plus pembrolizumab was associated with antitumor activity in advanced sarcoma across a range of sarcoma histologic subtypes, with a manageable safety profile. This combination therapy met its predefined primary study end point; further evaluation of T-VEC in combination with pembrolizumab for patients with select sarcoma subtypes is planned. Trial Registration ClinicalTrials.gov identifier: NCT03069378.
Collapse
Affiliation(s)
- Ciara M Kelly
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York.,Department of Sarcoma Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Timothy Bowler
- Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Rodrigo Munhoz
- Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ping Chi
- Weill Cornell Medical College, New York, New York.,Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Mark A Dickson
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York
| | - Mrinal M Gounder
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York
| | - Mary Louise Keohan
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York
| | - Sujana Movva
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Reena Dholakia
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Hamza Ahmad
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Matthew Biniakewitz
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Mercedes Condy
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Haley Phelan
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Margaret Callahan
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York.,Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Phillip Wong
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.,Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.,Immune Monitoring Facility, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sam Singer
- Weill Cornell Medical College, New York, New York.,Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Charlotte Ariyan
- Weill Cornell Medical College, New York, New York.,Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Edmund K Bartlett
- Weill Cornell Medical College, New York, New York.,Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Aimee Crago
- Weill Cornell Medical College, New York, New York.,Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sam Yoon
- Weill Cornell Medical College, New York, New York.,Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sinchun Hwang
- Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Joseph P Erinjeri
- Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Li-Xuan Qin
- Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York
| | - William D Tap
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York
| | - Sandra P D'Angelo
- Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York.,Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
25
|
von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Meyer C, Pappo AS, Parkes AM, Paz IB, Petersen IA, Poppe M, Riedel RF, Rubin B, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Bergman MA, George GV. NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw 2020; 18:1604-1612. [PMID: 33285515 DOI: 10.6004/jnccn.2020.0058] [Citation(s) in RCA: 149] [Impact Index Per Article: 37.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The NCCN Guidelines for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with soft tissue sarcomas. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including the development of a separate and distinct guideline for gastrointestinal stromal tumors (GISTs); reconception of the management of desmoid tumors; inclusion of further recommendations for the diagnosis and management of extremity/body wall, head/neck sarcomas, and retroperitoneal sarcomas; modification and addition of systemic therapy regimens for sarcoma subtypes; and revision of the principles of radiation therapy for soft tissue sarcomas.
Collapse
Affiliation(s)
| | | | | | - Edwin Choy
- 4Massachusetts General Hospital Cancer Center
| | - Mary Connelly
- 5The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
| | - Sarah Dry
- 6UCLA Jonsson Comprehensive Cancer Center
| | | | | | | | | | - Jade Homsi
- 10UT Southwestern Simmons Comprehensive Cancer Center
| | | | | | - Edward Kim
- 13Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
| | - David Liebner
- 5The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
| | | | | | - Christian Meyer
- 16The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
| | - Alberto S Pappo
- 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
| | | | | | | | - Matthew Poppe
- 21Huntsman Cancer Institute at the University of Utah
| | | | - Brian Rubin
- 23Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
| | | | - Jacob Shabason
- 25Abramson Cancer Center at the University of Pennsylvania
| | | | - Matthew B Spraker
- 27Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
| | - Melissa Zimel
- 28UCSF Helen Diller Family Comprehensive Cancer Center; and
| | | | | |
Collapse
|
26
|
Klemen ND, Kelly CM, Bartlett EK. The emerging role of immunotherapy for the treatment of sarcoma. J Surg Oncol 2020; 123:730-738. [PMID: 33259653 DOI: 10.1002/jso.26306] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 10/21/2020] [Accepted: 10/21/2020] [Indexed: 01/02/2023]
Abstract
Clinicians caring for patients with sarcoma founded the field of cancer immunotherapy. Despite this, contemporary success with immunotherapy for sarcoma has been limited. Here, we review immunotherapy for sarcoma including Coley's toxins, interleukin-2, adoptive cell transfer, and checkpoint blockade. We detail recent and ongoing efforts to combine checkpoint blockade with other immune modulators, surgery, or radiation. These results, along with ongoing investigations, have identified immunotherapeutic approaches as a promising avenue for progress in advanced sarcomas.
Collapse
Affiliation(s)
- Nicholas D Klemen
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ciara M Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Edmund K Bartlett
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| |
Collapse
|
27
|
Kearns C, Feighery R, Mc Caffrey J, Higgins M, Smith M, Murphy V, O’Reilly S, Horgan AM, Walshe J, McDermott R, Morris PG, Keane M, Martin M, Murphy C, Duffy K, Mihai A, Armstrong J, O’Donnell DM, Gallagher WM, Kelly CM, Kelly CM. Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland. Cancers (Basel) 2020; 12:cancers12071921. [PMID: 32708702 PMCID: PMC7409272 DOI: 10.3390/cancers12071921] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 07/11/2020] [Accepted: 07/13/2020] [Indexed: 11/16/2022] Open
Abstract
Cancer clinical trials (CCTs) are critical to translation and development of better therapies to improve outcomes. CCTs require adequate patient involvement but accrual rates are low globally. Several known barriers impede participation and knowing how subpopulations differ in understanding of CCTs can foster targeted approaches to aid accrual and advance cancer treatments. We conducted the first nationwide survey of 1089 patients attending 14 Irish cancer centres, assessing understanding of fundamental concepts in CCT methodology and factors that influence participation, to help tailor patient support for accrual to CCTs. Two-thirds (66%) of patients reported never having been offered a CCT and only 5% of those not offered asked to participate. Misunderstanding of clinical equipoise was prevalent. There were differences in understanding of randomisation of treatment by age (p < 0.0001), ethnicity (p = 0.035) and marital status (p = 0.013), and 58% of patients and 61% previous CCT participants thought that their doctor would ensure better treatment in CCTs. Females were slightly more risk averse. Males indicated a greater willingness to participate in novel drug trials (p = 0.001, p = 0.003). The study identified disparities in several demographics; older, widowed, living in provincial small towns and fewer years-educated patients had generally poorer understanding of CCTs, highlighting requirements for targeted support in these groups.
Collapse
Affiliation(s)
- Cathriona Kearns
- UCD Conway Institute Dublin, D04V1W8 Dublin, Ireland;
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Correspondence: (C.K.); (C.M.K.)
| | - Ronan Feighery
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
| | - John Mc Caffrey
- UCD School of Medicine, Mater Misericordiae University Hospital Dublin, D07AX57 Dublin, Ireland; (J.M.C.); (M.H.); (M.S.); (C.M.K.)
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
| | - Michaela Higgins
- UCD School of Medicine, Mater Misericordiae University Hospital Dublin, D07AX57 Dublin, Ireland; (J.M.C.); (M.H.); (M.S.); (C.M.K.)
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
| | - Martina Smith
- UCD School of Medicine, Mater Misericordiae University Hospital Dublin, D07AX57 Dublin, Ireland; (J.M.C.); (M.H.); (M.S.); (C.M.K.)
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
| | - Verena Murphy
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
| | - Seamus O’Reilly
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Cork University Hospital, T12DFK4 Cork, Ireland
| | - Anne M. Horgan
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- University Hospital Waterford, X91ER8E Waterford, Ireland
| | - Janice Walshe
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- St. Vincent University Hospital, D04YN63 Dublin, Ireland
| | - Ray McDermott
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Adelaide & Meath Hospital Incorporating the National Children’s Hospital (AMNCH), D24KNE0 Dublin, Ireland
| | - Patrick G. Morris
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Beaumont Hospital, D09A0KH Dublin, Ireland
| | - Maccon Keane
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Galway University Hospital, SW4794 Galway, Ireland
| | - Michael Martin
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Sligo General Hospital, F91H684 Sligo, Ireland
| | - Conleth Murphy
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Bon Secours Hospital, T12DV56 Cork, Ireland
| | - Karen Duffy
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Letterkenny General Hospital, F92FC82 Donegal, Ireland
| | - Alina Mihai
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Beacon Hospital, D18AK68 Dublin, Ireland
| | - John Armstrong
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- St. Luke’s Radiation Oncology Network, St Luke’s Hospital, Rathgar, D06HH36 Dublin, Ireland
| | - Dearbhaile M. O’Donnell
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- St. James’s Hospital, D08W9RT Dublin, Ireland
| | - William M. Gallagher
- UCD Conway Institute Dublin, D04V1W8 Dublin, Ireland;
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
| | - Ciara M. Kelly
- UCD School of Medicine, Mater Misericordiae University Hospital Dublin, D07AX57 Dublin, Ireland; (J.M.C.); (M.H.); (M.S.); (C.M.K.)
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
| | - Catherine M. Kelly
- UCD Conway Institute Dublin, D04V1W8 Dublin, Ireland;
- UCD School of Medicine, Mater Misericordiae University Hospital Dublin, D07AX57 Dublin, Ireland; (J.M.C.); (M.H.); (M.S.); (C.M.K.)
- Cancer Trials Ireland, Innovation House, Old Finglas Road, Glasnevin, D11KXN4 Dublin, Ireland; (R.F.); (V.M.); (S.O.); (A.M.H.); (J.W.); (R.M.); (P.G.M.); (M.K.); (M.M.); (C.M.); (K.D.); (A.M.); (J.A.); (D.M.O.)
- Correspondence: (C.K.); (C.M.K.)
| |
Collapse
|
28
|
Kelly CM, Rofcanin Y, Las Heras M, Ogbonnaya C, Marescaux E, Bosch MJ. Seeking an “i-deal” balance: Schedule-flexibility i-deals as mediating mechanisms between supervisor emotional support and employee work and home performance. Journal of Vocational Behavior 2020. [DOI: 10.1016/j.jvb.2019.103369] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Kelly CM, Strauss K, Arnold J, Stride C. The relationship between leisure activities and psychological resources that support a sustainable career: The role of leisure seriousness and work-leisure similarity. Journal of Vocational Behavior 2020. [DOI: 10.1016/j.jvb.2019.103340] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
30
|
Hassan A, Gullo G, O'Reilly S, Ruiz-Borrego M, Toomey S, Grogan L, Breathnach O, Morris PG, Walshe JM, Crown J, O'Mahony D, Falcon A, Egan K, Hernando A, Teiserskiene A, Kelly CM, Coate L, Hennessy BT. Abstract OT3-06-01: Phase Ib clinical trial of co PANlisib in combination with Trastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER2-positive bre Ast cancer (BC) “PANTHERA”-CTRIAL-IE 17-13. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot3-06-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:The phosphoinositide 3 kinase (PI3K) pathway is important in the oncogenic function of HER2. Aberrant activation of PI3K is implicated in resistance to trastuzumab and other HER2-targeted therapies and is frequent, with up to 22% of HER2 positive breast cancer having a PIK3CA mutation. Copanlisib is a pan-class 1 PI3K inhibitor administered i.v. with low nanomolar activity against both PI3Kα and PI3Kβ. Copanlisib has been shown to re-sensitise trastuzumab resistant cell lines to trastuzumab with synergism seen in some cell lines between copanlisib and HER2 targeted therapy.
Trial design: This is a phase Ib open label, single arm adaptive, multi-centre trial of copanlisib in combination with T-DM1. Eligible patients will receive T-DM1 at 3.6mg/kg i.v. on day 1 of a 21-day cycle plus copanlisib. Copanlisib will be administered i.v. according to the dose escalation scheme (dose level 1 is 45mg on days 1 and 8, dose level 2 is 60mg on days 1 and 8, dose level 3 is 60mg on days 1, 8, and 15). Dose level -1 will be 45 mg on day 1 in case dose de-escalation is needed. We will enrol 3 to 6 patients per dose level. All patients in each level must have completed at least the first cycle of therapy before enrolment in the next dose level. Patients not completing the first cycle for a reason other than toxicity will be replaced. Dose escalation and determination of the Maximum Tolerated Dose (MTD) will be based on the occurrence of Dose Limiting Toxicities (DLT).
Eligibility criteria:Eligible patients are those with unresectable locally advanced or metastatic HER2-positive BC who previously received trastuzumab and a taxane, separately or in combination. Participants must have adequate organ function and ECOG PS ≤ 2
Objectives:The primary objective is to determine the MTD for copanlisib in combination with T-DM1 in patients with pre-treated unresectable locally advanced or metastatic HER2-positive BC. Secondary objectives include evaluating the safety, efficacy and cardiotoxicity in patients treated with this regimen. Exploratory objectives include examining for predictive biomarkers in tumour tissue and blood or plasma and to examine molecular tumour adaptation to clinical trial therapy.
Statistical methods: Patients will be accrued in cohorts of 3 patients according to a standard 3+3 algorithm, with dose escalation and determination of MTD based on the occurrence of DLT, using the usual threshold probability of 33%. The final dose level will be expanded to include a total of 6 additional patients (expansion cohort).
Present accrual and target accrual:The trial will start accrual in October 2018. Maximum of 24 patients will be enrolled.
Citation Format: Hassan A, Gullo G, O'Reilly S, Ruiz-Borrego M, Toomey S, Grogan L, Breathnach O, Morris PG, Walshe JM, Crown J, O'Mahony D, Falcon A, Egan K, Hernando A, Teiserskiene A, Kelly CM, Coate L, Hennessy BT. Phase Ib clinical trial of coPANlisib in combination with Trastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER2-positive breAst cancer (BC) “PANTHERA”-CTRIAL-IE 17-13 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-06-01.
Collapse
Affiliation(s)
- A Hassan
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - G Gullo
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - S O'Reilly
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - M Ruiz-Borrego
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - S Toomey
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - L Grogan
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - O Breathnach
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - PG Morris
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - JM Walshe
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - J Crown
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - D O'Mahony
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - A Falcon
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - K Egan
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - A Hernando
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - A Teiserskiene
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - CM Kelly
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - L Coate
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - BT Hennessy
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| |
Collapse
|
31
|
Kelly CM. BUILDING A STATEWIDE COALITION TO ADDRESS ALZHEIMER’S DISEASE AND RELATED DEMENTIAS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- C M Kelly
- University of Nebraska at Omaha, Omaha, Nebraska, United States
| |
Collapse
|
32
|
Greally M, Kelly CM, Cercek A. HER2: An emerging target in colorectal cancer. Curr Probl Cancer 2018; 42:560-571. [DOI: 10.1016/j.currproblcancer.2018.07.001] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Revised: 04/20/2018] [Accepted: 07/09/2018] [Indexed: 02/07/2023]
|
33
|
Keegan NM, Walshe J, Gullo G, Kennedy J, Bulger K, Kelly CM, Crown J, Toomey S, Egan K, Kerr J, Given M, Hernando A, Teiserskiene A, Grogan L, Breathnach O, Morris PG, Keane M, Hennessy BT. Abstract OT3-06-05: A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-06-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The phosphoinositide 3 kinase (PI3K) pathway is important in the oncogenic function of HER2. Aberrent activation of PI3K is implicated in resistance to trastuzumab and other HER2-targeted therapies and is frequent, with up to 22% of HER2 positive breast cancer having a PIK3CA mutation. Copanlisib is a pan-class 1 PI3K inhibitor that shows particular activity against PI3Kα, the isoform encoded by the PIK3CA gene. Copanlisib has been shown to re-sensitise trastuzumab resistant cell lines to trastuzumab with synergism seen in some cell lines between copanlisib and HER2 targeted therapy.
Trial design
The study is a phase Ib/II open label, single arm adaptive, multi-centre trial of copanlisib in combination with trastuzumab. Eligible patients are treated with a dose escalation schedule of copanlisib IV on Days 1, 8 and 15 of a 28 day cycle with trastuzumab 2 mg/kg weekly (loading dose of 4 mg/kg in cycle 1). The phase II dose will be based on the maximum tolerated dose (MTD) established in Phase Ib. Patients are treated until radiologic or symptomatic progression, unacceptable toxicity, consent withdrawal or physician's decision.
Eligibility criteria
Eligible patients must have recurrent incurable or metastatic HER2-positive breast cancer that has progressed on at least one prior line of trastuzumab or T-DM1-based treatment regimen in this setting. Patients with treated and controlled brain metastases are eligible. Participants must have adequate organ function and ECOG PS ≤ 2. Patients recruited for the Phase II part of the study must have a PIK3CA mutation. Patients with uncontrolled arterial hypertension, uncontrolled diabetes or recent clinically serious infections are excluded.
Specific aims
The primary end point for the phase Ib part of this study is to determine the MTD for the combination. For the phase II study is anti-tumour efficacy, measured by Clinical Benefit Rate (CBR).
Secondary end points are evaluation of safety and tolerability, progression-free survival, time to treatment failure, duration of response and overall survival. Incorporated translational endpoints include examination of molecular tumor adaptation in tissue and blood. Given the role of PI3K in cellular glucose metabolism, an additional exploratory objective is to determine if quantitive reduction in metabolic signal on Positron Emission Tomography-Computed Tomography (PET-CT) is predictive of benefit from therapy.
Statistical methods
To establish the MTD, we use a modified 3+3 design where 3 additional patients will be accrued even if the first 3 patients accrued experience no dose limiting toxicities (DLT) in sequential cohorts for a planned 12 patients. To determine the CBR, a one sample exact binomial test with a one sided significance level of 5%, 19 evaluable patients will provide >80% power to detect a difference between the null hypothesis proportion of 30% for CBR versus the alternative hypothesis proportion of 65%.
Present accrual and target accrual
There are 9 patients recruited so far to the phase Ib part of this study. Target accrual is 12 and for phase II is 19 patients.
Contact information for people with a specific interest in the trial
Prof Bryan Hennessy, Beaumont Hospital, Dublin Ireland
Funded by Bayer
Citation Format: Keegan NM, Walshe J, Gullo G, Kennedy J, Bulger K, Kelly CM, Crown J, Toomey S, Egan K, Kerr J, Given M, Hernando A, Teiserskiene A, Grogan L, Breathnach O, Morris PG, Keane M, Hennessy BT. A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER” [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-06-05.
Collapse
Affiliation(s)
- NM Keegan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Walshe
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - G Gullo
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Kennedy
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - K Bulger
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - CM Kelly
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Crown
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - S Toomey
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - K Egan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Kerr
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - M Given
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - A Hernando
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - A Teiserskiene
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - L Grogan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - O Breathnach
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - PG Morris
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - M Keane
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - BT Hennessy
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| |
Collapse
|
34
|
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23:1004. [PMID: 28777785 DOI: 10.1038/nm0817-1004c] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
35
|
Abstract
INTRODUCTION Colorectal cancer is a significant global health issue with over 1 million cases diagnosed annually throughout the world. 15% of patients diagnosed with colorectal cancer will have liver metastases and 60% will develop liver metastases if they have metastatic disease. Oligometastatic colorectal cancer confined to the liver represents an intermediate state in the evolution of metastatic capacity that opens the opportunity for local interventions. Areas covered: The literature supports long-term survival if patients undergo liver resection of colorectal metastases. This article reviews the liver-directed therapeutic strategies available for the management of metastatic liver disease including hepatic arterial infusion therapy, radiofrequency ablation, radiation therapy and transarterial chemoembolization. Expert commentary: Great advances have been made with the use of liver directed therapies. In the USA using hepatic arterial infusions with FUDR and Decadron along with systemic therapy, 5 year survivals after liver resection have improved. In Europe with the use of HAI of Oxaliplatin, more patients have been able to get to resection and have obtained higher survival rates, even in second line therapy. New advances in ablative therapy have improved results to get all disease treated at resection for the treatment of reccurrence.
Collapse
Affiliation(s)
- Ciara M Kelly
- a Department of Graduate Medical Education , Memorial Sloan Kettering Cancer Center , New York , USA
| | - Nancy E Kemeny
- b Memorial Sloan-Kettering Cancer Center , Weill Medical College of Cornell University , New York , USA
| |
Collapse
|
36
|
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23:703-713. [PMID: 28481359 PMCID: PMC5461196 DOI: 10.1038/nm.4333] [Citation(s) in RCA: 2161] [Impact Index Per Article: 308.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 04/04/2017] [Indexed: 02/07/2023]
Abstract
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible.
Collapse
Affiliation(s)
- Ahmet Zehir
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ryma Benayed
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ronak H Shah
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Aijazuddin Syed
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Sumit Middha
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Hyunjae R Kim
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Preethi Srinivasan
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jianjiong Gao
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Debyani Chakravarty
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Sean M Devlin
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Matthew D Hellmann
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - David A Barron
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Alison M Schram
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Meera Hameed
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Snjezana Dogan
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Dara S Ross
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jaclyn F Hechtman
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Deborah F DeLair
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - JinJuan Yao
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Diana L Mandelker
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Donavan T Cheng
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Raghu Chandramohan
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Abhinita S Mohanty
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ryan N Ptashkin
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Gowtham Jayakumaran
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Meera Prasad
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Mustafa H Syed
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | | | - Zhen Y Liu
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Khedoudja Nafa
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Laetitia Borsu
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Justyna Sadowska
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jacklyn Casanova
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ruben Bacares
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Iwona J Kiecka
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Anna Razumova
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Julie B Son
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Lisa Stewart
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Tessara Baldi
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Kerry A Mullaney
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Hikmat Al-Ahmadie
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Efsevia Vakiani
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Adam A Abeshouse
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Alexander V Penson
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Philip Jonsson
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Niedzica Camacho
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Matthew T Chang
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Helen H Won
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Benjamin E Gross
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ritika Kundra
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Zachary J Heins
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Hsiao-Wei Chen
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Sarah Phillips
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Hongxin Zhang
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jiaojiao Wang
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Angelica Ochoa
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jonathan Wills
- Information Systems, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Michael Eubank
- Information Systems, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Stacy B Thomas
- Information Systems, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Stuart M Gardos
- Information Systems, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Dalicia N Reales
- Clinical Research Administration, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jesse Galle
- Clinical Research Administration, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Robert Durany
- Clinical Research Administration, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Roy Cambria
- Clinical Research Administration, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Wassim Abida
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Andrea Cercek
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Darren R Feldman
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Mrinal M Gounder
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - A Ari Hakimi
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - James J Harding
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Gopa Iyer
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Yelena Y Janjigian
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Emmet J Jordan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ciara M Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Maeve A Lowery
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Luc G T Morris
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Antonio M Omuro
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Nitya Raj
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Pedram Razavi
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | | | - Neerav Shukla
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Tara E Soumerai
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Anna M Varghese
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Rona Yaeger
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jonathan Coleman
- Clinical Research Administration, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Bernard Bochner
- Clinical Research Administration, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Gregory J Riely
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Leonard B Saltz
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Howard I Scher
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Paul J Sabbatini
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Mark E Robson
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - David S Klimstra
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Barry S Taylor
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jose Baselga
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Nikolaus Schultz
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - David M Hyman
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Maria E Arcila
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - David B Solit
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Marc Ladanyi
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Michael F Berger
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| |
Collapse
|
37
|
Krop I, Abramson V, Colleoni M, Holmes FA, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Guculp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Kelly CM, Uppal H, Tudor IC, Peterson A, Winer E, Yardley DA. Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- I Krop
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - V Abramson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Colleoni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - FA Holmes
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Estevez
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Hart
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Awada
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - C Zamagni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - P Morris
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Schwartzberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - S Chan
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - D Wheatley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Guculp
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Biganzoli
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - J Steinberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Gianni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Trudeau
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - CM Kelly
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - H Uppal
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - IC Tudor
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Peterson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - DA Yardley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| |
Collapse
|
38
|
Keegan NM, Milewski M, Kelly CM, Murphy V, Chao C, Walsh J, Kennedy MJ, O'Connor M, Murphy C, O'Reilly S, Keane M, Duffy K, Hennessy B, Morris PG. Abstract OT3-04-03: The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-04-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND
For Estrogen Receptor (ER) positive, early stage breast cancer, the 21 gene Recurrence Score (RS) has clinical use both as a prognostic tool and to predict chemotherapy benefit. The availability of this tool in Ireland has led to a reduction in the use of adjuvant chemotherapy for women with lymph node (LN) negative disease. However, the RS is not routinely funded for patients with LN positive (LN+) breast cancer in Ireland. In addition, there are limited international data on the use of this tool in the preoperative setting. In this prospective observational study, we are investigating whether access to the 21 gene RS leads to a reduction in the receipt of chemotherapy for patients with ER+, LN+ breast cancer, and to correlate the 21 gene RS with response to preoperative systemic therapy.
TRIAL DESIGN
This is a national, multi-site, prospective, observational study that will examine the impact of the 21 gene RS on chemotherapy recommendations in both the neoadjuvant and adjuvant setting. Prior to and following tumor testing with the 21 gene RS, Physicians will complete a questionnaire which details type and strength of systemic therapy recommendations.
ELIGIBILITY
Cohort 1 (postoperative) will include patients with ER+ tumors of any size with involvement of 1-3 lymph nodes (N1 including micrometastases). Cohort 2 (preoperative) will include patients with ER+, T2-T4 tumors with biopsy proven nodal metastases. Both cohorts will have ECOG PS 0 or 1 and be fit for consideration of chemotherapy as determined by the Investigator.
SPECIFIC AIMS
The primary endpoint is the percentage reduction in the number of patients for whom treating physicians recommend chemotherapy after testing with 21 gene RS. Secondary endpoints include the correlation between the 21 gene RS and residual cancer burden score, as well as pathological, clinical and radiological response rates. The economic impact of the 21 gene RS in ER+, LN+ will also be assessed.
STATISTICAL METHODS
The sample size is based on similar decision impact studies conducted in other countries. Physician recommendations for chemotherapy pre 21-gene RS and recommendations post 21-gene RS testing will be compared and percentage change estimated with 95% confidence intervals. For secondary endpoints, the Pearson correlation coefficient (rho) will be used to examine the strength of the correlation between the 21 gene RS category and response. A budget impact model will be used to estimate the cost reduction in adjuvant chemotherapy as a result of 21-gene RS testing.
PRESENT ACCRUAL AND TARGET ACCRUAL
Target accrual is 75 in each of the neoadjuvant and adjuvant cohorts to total 150 patients.
Supported by Genomic Health.
Citation Format: Keegan NM, Milewski M, Kelly CM, Murphy V, Chao C, Walsh J, Kennedy MJ, O'Connor M, Murphy C, O'Reilly S, Keane M, Duffy K, Hennessy B, Morris PG. The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-04-03.
Collapse
Affiliation(s)
- NM Keegan
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - M Milewski
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - CM Kelly
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - V Murphy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - C Chao
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - J Walsh
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - MJ Kennedy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - M O'Connor
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - C Murphy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - S O'Reilly
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - M Keane
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - K Duffy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - B Hennessy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - PG Morris
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| |
Collapse
|
39
|
Kelly CM, Shahrokni A. From Shelf to Bedside-Wearable Electronic Activity Monitoring Technologies Might Assist Oncologists in Functional Performance Status Assessment of Older Cancer Patients. Clin Colorectal Cancer 2016; 16:S1533-0028(16)30256-0. [PMID: 28040407 DOI: 10.1016/j.clcc.2016.11.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2016] [Revised: 09/23/2016] [Accepted: 11/14/2016] [Indexed: 12/27/2022]
Affiliation(s)
- Ciara M Kelly
- Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
| | - Armin Shahrokni
- Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Geriatrics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
40
|
Watson GA, Kelly D, Prior L, Stanley E, MacEneaney O, Walsh T, Kelly CM. An unusual case of basal cell carcinoma of the vulva with lung metastases. Gynecol Oncol Rep 2016; 18:32-35. [PMID: 27830172 PMCID: PMC5094149 DOI: 10.1016/j.gore.2016.10.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 10/17/2016] [Accepted: 10/23/2016] [Indexed: 12/01/2022] Open
Abstract
Basal cell carcinoma (BCC) is the most common non-melanomatous skin cancer, typically arising in sun-exposed areas such as the head and neck. Defective signaling through the Hedgehog (HH) signaling pathway forms the molecular basis for BCC. Surgery remains the mainstay of treatment. Basal cell carcinoma of the genital tract is rare as is metastatic BCC. We report a case of metastatic BCC in a young woman with previously resected vulval BCC presenting six years later with inguinal nodal recurrence and multiple lung metastases. This case describes a rare case of basal cell carcinoma of the vulva. In addition, metastatic spread to the lungs is another rare occurrence. Multidisciplinary team discussion is paramount in guiding management. Vismodegib is an exciting new treatment option for advanced disease. Vigilant monitoring and/or early surgical excision of any suspicious skin lesions is paramount.
Collapse
Affiliation(s)
- G A Watson
- Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St., Dublin 7, Ireland
| | - D Kelly
- Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St., Dublin 7, Ireland
| | - L Prior
- Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St., Dublin 7, Ireland
| | - E Stanley
- Department of Radiology, Mater Misericordiae University Hospital, Eccles St., Dublin 7, Ireland
| | - O MacEneaney
- Department of Pathology, Mater Misericordiae University Hospital, Eccles St., Dublin 7, Ireland
| | - T Walsh
- Department of Gynaecology, Mater Misericordiae University Hospital, Eccles St., Dublin 7, Ireland
| | - C M Kelly
- Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St., Dublin 7, Ireland
| |
Collapse
|
41
|
Abstract
Gastric cancer is a biologically heterogeneous tumor. The identification of human epidermal growth factor receptor-2 (HER2) biomarker overexpression in gastric cancer represented a significant step towards unraveling the molecular complexity of this disease. Trastuzumab in combination with chemotherapy, in the first-line setting of patients with metastatic, HER2-positive gastric and gastroesophageal, represents the first targeted therapeutic to demonstrate improvement in response rate and survival in gastric cancer. However, not all patients with HER2-positive gastric cancer respond to trastuzumab and the majority of patients who do initially benefit from trastuzumab develop resistance to it. Advances in molecular oncology and cancer genomics have helped to classify gastric cancer into molecularly distinct subtypes. This information informs research efforts investigating the etiology of mechanisms of resistance to HER2-directed therapy and guides clinical investigation in methods to overcome this resistance. This article reviews anti-HER2-therapies that are currently used as standard of care in advanced, HER2-positive, breast cancer and are now under investigation as monotherapy and in combination with chemotherapy and/or a second HER2-directed agent in advanced HER2-positive gastric cancer. The future directions of clinical investigation in HER2-positive gastric cancer are also discussed including: novel HER2-directed therapies, the pharmacokinetics and pharmacodynamics of anti-HER2-therapies, the role of functional imaging, the potential of patient derived xenograft preclinical models and the importance of tumor genomic sequencing.
Collapse
Affiliation(s)
- Ciara M Kelly
- Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Yelena Y Janjigian
- Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;; Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Cornell Medical College, New York, NY 10065, USA
| |
Collapse
|
42
|
Abstract
Objective Reports suggest that patients with oral cancer delay seeking help because they are unaware of the symptoms. The majority of adults (95%) engage with news reports and 40% read newspapers. Newspaper oral cancer stories may influence awareness and health-seeking behaviour. The aim of this study was to explore how oral cancer is portrayed in UK newspaper print media.Design Qualitative content analysis of articles from ten newspapers with the widest UK print circulation. All articles using the terms 'mouth cancer' and 'oral cancer' over a three year period were retrieved. Duplicates, non-cancer and non-human articles were excluded.Results 239 articles were analysed. Common topics included 'recent research', 'survivor stories', 'health information' and 'celebrity linkage'. Articles were often emotive, featuring smoking, alcohol, sex and celebrity. Articles lacked a proper evidence base and often failed to provide accurate information about signs and symptoms, information about prevention and signposting to treatment.Conclusions Opportunities to save lives are being missed. Further work to improve social responsibility in the media and develop guidance to enhance the quality of information, health reporting and signposting to help are indicated.
Collapse
Affiliation(s)
- C M Kelly
- Cardiff University, Dental Public Health, School of Dentistry, Heath Park, Cardiff, CF14 4XY
| | - I G Johnson
- Cardiff University, Dental Public Health, School of Dentistry, Heath Park, Cardiff, CF14 4XY
| | - M Z Morgan
- Cardiff University, Dental Public Health, School of Dentistry, Heath Park, Cardiff, CF14 4XY
| |
Collapse
|
43
|
Precious SV, Kelly CM, Reddington AE, Vinh NN, Stickland RC, Pekarik V, Scherf C, Jeyasingham R, Glasbey J, Holeiter M, Jones L, Taylor MV, Rosser AE. FoxP1 marks medium spiny neurons from precursors to maturity and is required for their differentiation. Exp Neurol 2016; 282:9-18. [PMID: 27154297 PMCID: PMC4920670 DOI: 10.1016/j.expneurol.2016.05.002] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Revised: 04/25/2016] [Accepted: 05/01/2016] [Indexed: 12/11/2022]
Abstract
Identifying the steps involved in striatal development is important both for understanding the striatum in health and disease, and for generating protocols to differentiate striatal neurons for regenerative medicine. The most prominent neuronal subtype in the adult striatum is the medium spiny projection neuron (MSN), which constitutes more than 85% of all striatal neurons and classically expresses DARPP-32. Through a microarray study of genes expressed in the whole ganglionic eminence (WGE: the developing striatum) in the mouse, we identified the gene encoding the transcription factor Forkhead box protein P1 (FoxP1) as the most highly up-regulated gene, thus providing unbiased evidence for the association of FoxP1 with MSN development. We also describe the expression of FoxP1 in the human fetal brain over equivalent gestational stages. FoxP1 expression persisted through into adulthood in the mouse brain, where it co-localised with all striatal DARPP-32 positive projection neurons and a small population of DARPP-32 negative cells. There was no co-localisation of FoxP1 with any interneuron markers. FoxP1 was detectable in primary fetal striatal cells following dissection, culture, and transplantation into the adult lesioned striatum, demonstrating its utility as an MSN marker for transplantation studies. Furthermore, DARPP-32 expression was absent from FoxP1 knock-out mouse WGE differentiated in vitro, suggesting that FoxP1 is important for the development of DARPP-32-positive MSNs. In summary, we show that FoxP1 labels MSN precursors prior to the expression of DARPP-32 during normal development, and in addition suggest that FoxP1 labels a sub-population of MSNs that are not co-labelled by DARPP-32. We demonstrate the utility of FoxP1 to label MSNs in vitro and following neural transplantation, and show that FoxP1 is required for DARPP-32 positive MSN differentiation in vitro.
Collapse
Affiliation(s)
- S V Precious
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - C M Kelly
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - A E Reddington
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - N N Vinh
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - R C Stickland
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - V Pekarik
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom; Central European Institute of Technology (CEITEC), Institute of Anatomy, Masaryk University, A1/064, Kamenice 3, 625 00 Brno, Czech Republic
| | - C Scherf
- Department of Obstetrics and Gynaecology, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom
| | - R Jeyasingham
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - J Glasbey
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - M Holeiter
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - L Jones
- MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom
| | - M V Taylor
- Molecular Biosciences Research Division, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom
| | - A E Rosser
- Brain Repair Group, Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, United Kingdom; MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
| |
Collapse
|
44
|
Bond KS, Jorm AF, Kitchener BA, Kelly CM, Chalmers KJ. Development of guidelines for family and non-professional helpers on assisting an older person who is developing cognitive impairment or has dementia: a Delphi expert consensus study. BMC Geriatr 2016; 16:129. [PMID: 27387756 PMCID: PMC4936264 DOI: 10.1186/s12877-016-0305-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 06/21/2016] [Indexed: 01/08/2023] Open
Abstract
Background Assisting a person with dementia can lead to significant carer burden and possible negative outcomes for the person. Using the Delphi method, this study developed expert consensus guidelines for how family and non-professional carers should assist a person who is developing cognitive impairment, or has dementia or delirium. Methods A systematic search of websites, books and journal articles was conducted to develop a questionnaire containing items about the knowledge, skills and actions needed for assisting a person who is developing cognitive impairment, or has dementia or delirium. These items were rated over three rounds by two international expert panels comprising professionals specialising in research or treatment of dementia, and dementia carer advocates. Results A total of 65 participants (43 in the professional panel and 22 in the carer advocate panel) completed all three survey rounds. Of the 656 survey items that were rated, a total of 389 items were endorsed by at least 80 % of each panel. The endorsed items formed the basis of a guidelines document that explains what family and non-professional carers need to know and do when assisting a person who is developing cognitive impairment, or has dementia or delirium. Conclusions The two groups of experts were able to reach substantial consensus on how to assist a person who is developing cognitive impairment, or has dementia or delirium. Electronic supplementary material The online version of this article (doi:10.1186/s12877-016-0305-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- K S Bond
- Mental Health First Aid Australia, Level 6, 369 Royal Parade, Parkville, VIC, 3052, Australia.
| | - A F Jorm
- Centre for Mental Health, Melbourne School of Population and Global Health, The University of Melbourne, Level 4, 207 Bouverie Street, Parkville, VIC, 3010, Australia
| | - B A Kitchener
- Mental Health First Aid Australia, Level 6, 369 Royal Parade, Parkville, VIC, 3052, Australia.,School of Psychology, Deakin University, 1 Gheringhap Street, Geelong, VIC, 3220, Australia
| | - C M Kelly
- Mental Health First Aid Australia, Level 6, 369 Royal Parade, Parkville, VIC, 3052, Australia.,School of Psychology, Deakin University, 1 Gheringhap Street, Geelong, VIC, 3220, Australia
| | - K J Chalmers
- Mental Health First Aid Australia, Level 6, 369 Royal Parade, Parkville, VIC, 3052, Australia
| |
Collapse
|
45
|
Kelly CM, McCaffrey JA, Kelly CM. Abstract P5-09-14: Understanding and attitudes towards cancer clinical research among breast cancer patients compared to the general population: Prospective cross-sectional study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-09-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In 2009 the Irish Platform for Patients' Organisations, Science and Industry (IPPOSI) commissioned research to ascertain the Irish public's understanding and opinion of clinical research (CR) and clinical trials (CT). The aim of this study was to compare attitudes and understanding regarding participation in cancer CT in breast cancer pts treated in a disadvantaged area to those of the general population surveyed by IPPOSI.
Methods: Eligibility criteria included: a cancer diagnosis (dx), attendance at the Mater Hospital, able to complete a questionnaire. We examined: a) demographics b) cancer dx, c) understanding and attitudes towards CR, 4) discussion regarding participation and 5) experience on a CT. Comparison was made between this study and the IPPOSI survey of 1000 members of the Irish public.
Results: 356 pts completed the questionnaire. The majority (58%, n=206) had a history of breast cancer and these results focus on this group. The median age was 56 yr (range: 28-81 yr), 19% were ≥ 65 yr. 87% had adjuvant disease, 13% had advanced cancer. 36% did not complete 2nd level education and 38% reported inaccurate cancer details. Most reported understanding the terms 'CR' (91%) and 'CT' (84%). Nearly half (46%) expressed ambivalence or would decline participation in a CT. Reasons offered for this attitude include: fear of side effects (46%), requiring more information (24%), and inappropriate candidate/age (10%). There was a significant association between the decision to participate in a CT and participant's level of education (p=0.02) and cancer stage (p=0.01). Participants with a low level of education were more likely to decline participation (57%). Participants with advanced cancer were more likely to agree to participate (79%). 47% of the study population used support to help in the decision making process. Family (40%), GP (7%) and members of the CT team (10%) were the forms of support most commonly accessed. 33% had the option to participate in a CT. 86% (n=59) accepted. 9% (n=6) were ineligible. The majority of pts who took part in a CT reported a positive experience (89%) and a positive impact on their quality of life (82.5%). Over 90% of pts would recommend or take part in another CT.
In comparison with the IPPOSI study, breast cancer pts displayed a greater understanding than the Irish public of the terms 'CR' (91% vs 52%) and 'CT' (84% vs 75%). They were more willing than the Irish public to participate in CR (73% vs 42%) and more specifically research involving the donation of blood (78% vs 71%) or supply of medical details (92% vs 67%). However, there was a similar level of reluctance to participate in a 'CT' amongst both groups.
Citation Format: Kelly CM, McCaffrey JA, Kelly CM. Understanding and attitudes towards cancer clinical research among breast cancer patients compared to the general population: Prospective cross-sectional study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-09-14.
Collapse
Affiliation(s)
- CM Kelly
- Mater Misericordiae University Hospital, Dublin, Ireland; Irish Platform for Patients' Organisations, Science and Industry (IPPOSI), Dublin, Ireland
| | - JA McCaffrey
- Mater Misericordiae University Hospital, Dublin, Ireland; Irish Platform for Patients' Organisations, Science and Industry (IPPOSI), Dublin, Ireland
| | - CM Kelly
- Mater Misericordiae University Hospital, Dublin, Ireland; Irish Platform for Patients' Organisations, Science and Industry (IPPOSI), Dublin, Ireland
| |
Collapse
|
46
|
Lelos MJ, Morgan RJ, Kelly CM, Torres EM, Rosser AE, Dunnett SB. Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease. Exp Neurol 2016; 278:54-61. [PMID: 26851542 PMCID: PMC4801014 DOI: 10.1016/j.expneurol.2016.02.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2015] [Revised: 01/25/2016] [Accepted: 02/02/2016] [Indexed: 11/29/2022]
Abstract
Background Patients suffering from Parkinson's disease (PD) display cognitive and neuropsychiatric dysfunctions, especially with disease progression. Although these impairments have been reported to impact more heavily upon a patient's quality of life than any motor dysfunctions, there are currently no interventions capable of adequately targeting these non-motor deficits. Objectives Utilizing a rodent model of PD, we investigated whether cell replacement therapy, using intrastriatal transplants of human-derived ventral mesencephalic (hVM) grafts, could alleviate cognitive and neuropsychiatric, as well as motor, dysfunctions. Methods Rats with unilateral 6-hydroxydopamine lesions to the medial forebrain bundle were tested on a complex operant task that dissociates motivational, visuospatial and motor impairments sensitive to the loss of dopamine. A subset of lesioned rats received intrastriatal hVM grafts of ~ 9 weeks gestation. Post-graft, rats underwent repeated drug-induced rotation tests and were tested on two versions of the complex operant task, before post-mortem analysis of the hVM tissue grafts. Results Post-graft behavioural testing revealed that hVM grafts improved non-motor aspects of task performance, specifically visuospatial function and motivational processing, as well as alleviating motor dysfunctions. Conclusions We report the first evidence of human VM cell grafts alleviating both non-motor and motor dysfunctions in an animal model of PD. This intervention, therefore, is the first to improve cognitive and neuropsychiatric symptoms long-term in a model of PD. Non-motor dysfunctions affect quality of life in Parkinson's disease. We tested whether human-derived foetal dopamine cells could improve these deficits. Human dopamine cells improved rotational bias and movement impairments in a rat model. Non-motor dysfunctions, specifically visuospatial and motivational deficits, improved. This is the first evidence of improved non-motor deficits from human dopamine cells.
Collapse
Affiliation(s)
- M J Lelos
- Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, Wales CF10 3AX, UK.
| | - R J Morgan
- Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, Wales CF10 3AX, UK
| | - C M Kelly
- Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, Wales CF10 3AX, UK
| | - E M Torres
- Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, Wales CF10 3AX, UK
| | - A E Rosser
- Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, Wales CF10 3AX, UK
| | - S B Dunnett
- Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, Wales CF10 3AX, UK
| |
Collapse
|
47
|
Kelly CM, El Bassiouni M, Bennett MW, Crush L, McEneaney P, O'Suilleabhain C, Power DG. Borderline resectable pancreatic adenocarcinoma, is conversion therapy realistic? Acta Oncol 2014; 53:1268-71. [PMID: 24739060 DOI: 10.3109/0284186x.2014.887856] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Ciara M Kelly
- Department of Medical Oncology, Mercy University Hospital , Cork , Ireland
| | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
The introduction of targeted therapy has ushered in the era of personalized medicine in cancer therapy. The increased understanding of tumor heterogeneity has led to the determination of specific targets that can be exploited in treatment. This review highlights approved drugs in different therapeutic classes, including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, drugs targeted to the human epidermal growth factor receptor 2, BRAF-mutation targeted drugs, anti-epidermal growth factor receptor inhibitors, and anti-vascular endothelial growth factor therapy. There have not been elderly patient-specific trials of these therapies. Most of the data are extrapolated from larger trials in which older patients generally were a fraction of the participants. Therapeutic recommendations are made on the basis of this analysis with the recognition that the older clinical trial participants may not be representative of patients seen in daily practice. Patient selection and geriatric evaluation are critical for appropriate drug selection, dosing, and monitoring. With care, these therapies are a major step forward in the safe and effective treatment of older patients with cancer.
Collapse
Affiliation(s)
- Ciara M Kelly
- Ciara M. Kelly and Derek G. Power, Mercy University Hospital, Cork, Ireland; and Stuart M. Lichtman, Memorial Sloan Kettering Cancer Center, Commack, NY
| | - Derek G Power
- Ciara M. Kelly and Derek G. Power, Mercy University Hospital, Cork, Ireland; and Stuart M. Lichtman, Memorial Sloan Kettering Cancer Center, Commack, NY
| | - Stuart M Lichtman
- Ciara M. Kelly and Derek G. Power, Mercy University Hospital, Cork, Ireland; and Stuart M. Lichtman, Memorial Sloan Kettering Cancer Center, Commack, NY.
| |
Collapse
|
49
|
O'Kane GM, Lyons T, McDonald I, Mulligan N, Moloney FJ, Murray D, Kelly CM. Vismodegib in the treatment of advanced BCC. Ir Med J 2014; 107:215-216. [PMID: 25226719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Basal-cell carcinoma (BCC) is the most commonly diagnosed malignancy, comprising over 80 per thousand of non-melanoma skin cancers. Surgical excision is adequate treatment for most BCC's. Options are however limited for the minority of patients presenting with locally advanced inoperable or metastatic BCC. The Hedgehog signalling pathway is a critical driver in the pathogenesis of both sporadic and hereditary BCC. On 31st January 2012, based on a phase II clinical trial the US Food and Drug Administration approved Vismodegib (Erivedge, Roche) a first-in-class, small-molecule oral Hedgehog-inhibitor for the treatment of locally advanced inoperable and metastatic BCC. We present our experience treating the first Irish patient with this agent.
Collapse
|
50
|
Rinaldi F, Hartfield EM, Crompton LA, Badger JL, Glover CP, Kelly CM, Rosser AE, Uney JB, Caldwell MA. Cross-regulation of Connexin43 and β-catenin influences differentiation of human neural progenitor cells. Cell Death Dis 2014; 5:e1017. [PMID: 24457961 PMCID: PMC4040652 DOI: 10.1038/cddis.2013.546] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2013] [Revised: 10/30/2013] [Accepted: 11/04/2013] [Indexed: 12/03/2022]
Abstract
Connexin43 (Cx43) is the most widely and abundantly expressed gap junction (GJ) protein and it is strongly associated with the regulation of cell cycle progression. Emerging roles for Cx43 in cell adhesion and migration during neural differentiation have also been recently recognized, and this has emphasized the involvement of Cx43 in different physiological process beyond its role as a GJ protein. In this study, we explore the function of Cx43 in the differentiation of human neural progenitor cells (hNPCs) using viral vectors that mediate the overexpression or knockdown of the protein. Results showed that in the absence of this protein fetal cortex-derived hNPCs differentiated toward a neuronal phenotype at expenses of a glial phenotype. Furthermore, the silencing of Cx43 did not affect hNPC proliferation rate or numbers of apoptotic cells. The increase in the number of neurons was not recapitulated when GJ intercellular communications were pharmacologically blocked, and this suggested that Cx43 was influencing hNPCs differentiation with a GJ-independent effect. In addition, Cx43 knockdown significantly increased β-catenin signaling, which has been shown to regulate the transcription of pro-neuronal genes during embryonic neural development. Our results add further support to the hypothesis that Cx43 protein itself regulates key signaling pathways during development and neurogenesis beyond its role as GJ protein.
Collapse
Affiliation(s)
- F Rinaldi
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - E M Hartfield
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - L A Crompton
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - J L Badger
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - C P Glover
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - C M Kelly
- Brain Repair Group, School of Biosciences, Life Science Building, University of Cardiff, Cardiff, UK
| | - A E Rosser
- Brain Repair Group, School of Biosciences, Life Science Building, University of Cardiff, Cardiff, UK
- Department of Neurology, School of Medicine, University of Cardiff, Cardiff, UK
| | - J B Uney
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - M A Caldwell
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| |
Collapse
|